# US 2020/0399379 A1 · Fusion immunomodulatory proteins and methods for making same

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399379 A1
- Document ID: US20200399379A1
- Status: Published application
- Kind: A1
- Application number: 17/010,178
- Filed: 2020-09-02
- Published: 2020-12-24
- Earliest claimed: 2013-03-12
- Assignees: Biocon Limited
- Applicants: Biocon Ltd.
- Inventors: NAGARAJ GOVINDAPPA; MARIA MELINA SOARES; KEDERNATH SASTRY
- Web page: https://patentgrep.com/patent/US20200399379A1

## CPC

- C07K 16/2863: {against receptors for growth factors, growth regulators}
- A61P 35/00: Antineoplastic agents
- A61P 37/02: Immunomodulators
- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 14/71: for growth factors; for growth regulators
- C07K 16/2818: {against CD28 or CD152}
- C12N 15/62: DNA sequences coding for fusion proteins
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- C07K 2317/40: characterized by post-translational modification
- C07K 2317/526: CH3 domain
- C07K 2317/90: characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K 2319/00: Fusion polypeptide
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates generally to the field of generating recombinant chimeric fusion proteins to be used in the cancer therapy, and more specifically, to fusion molecules of Anti-EGFR1-TGFβRII, Anti-EGFR1-PD1 and Anti-CTLA4-PD1 and methods of generating same, wherein the methods reduce production costs and increase homogeneity of the recombinant chimeric fusion proteins.

## Claims

### Claim 1

A fusion protein comprising a targeting moiety and an immunomodulating moiety exhibiting bi-specificiity, wherein the targeting moiety and the immunomodulating moiety are linked by an amino acid spacer encoded by nucleotide sequence SEQ ID NO: 4, wherein the immunomodulating moiety is encoded by nucleotide sequence SEQ ID NO: 3 or SEQ ID NO: 7, wherein the targeting moiety is an anti-EGFR1 antibody encoded by nucleotide sequences consisting of SEQ ID NO: 1 and SEQ ID NO: 2, wherein the encoded by nucleotide sequence SEQ ID NO: 3 or SEQ ID NO: 7 is attached via SEQ ID NO: 4 to the C-terminus of SEQ ID NO 1 or SEQ ID NO: 2.

### Claim 2

A fusion protein comprising a targeting moiety and an immunomodulating moiety exhibiting bi-specificiity, wherein the targeting moiety and the immunomodulating moiety are linked by an amino acid spacer encoded by nucleotide sequence SEQ ID NO: 4, wherein the immunomodulating moiety is encoded by nucleotide sequence SEQ ID NO: 3 or SEQ ID NO: 7, wherein the targeting moiety is an anti-EGFR1 antibody encoded by nucleotide sequences consisting of SEQ ID NO: 5 and SEQ ID NO: 6, wherein the encoded by nucleotide sequence SEQ ID NO: 3 or SEQ ID NO: 7 is attached via SEQ ID NO: 4 to the C-terminus of SEQ ID NO 5 or SEQ ID NO: 6.